Shire also announced, on January 24th, that it had completed the merger of ViroPharma with one of its subsidiaries. Shire taps ex-investment banker Susan Kilsby to chair its board (FiercePharma).
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on ...
Uncomplicated skin infections account for almost 200 million physician-office visits in the USA annually. Treating these infections is estimated to cost in excess of US$350 million each year. The ...
Served as a speaker or a member of a speakers bureau for: F. Hoffmann-La Roche Ltd (Europe); Astellas Pharma, Inc. Received grants for clinical research from: Wyeth Pharmaceuticals Inc. Clinical ...
6 NIHR Biomedical Research Centre at Guy's and St Thomas’ NHS Foundation Trust and King's College London, London, UK Objectives We investigated long-term (to 25 years) seizure prognosis and survival ...